GlassScriptPhysician profile
Larry F Weisner
NPI 1841252459
$618.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $38.64 · 2021: $18.05 · 2022: $123.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $239.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $123.43 | 2022 | |
| Ucb, INC. | $52.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.61 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.18 | 2019-2020 | |
| Amgen INC. | $25.69 | 2019 | |
| Sk Life Science, INC. | $18.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.27 | 2019 | |
| Allergan, INC. | $15.77 | 2019 | |
| Genzyme Corporation | $15.32 | 2019 | |
| Emd Serono, INC. | $14.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Weisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.